Printer Friendly

MedImpact Study Demonstrates VBBD Improves Adherence to Diabetes Medication.

SAN DIEGO -- A recent study led by MedImpact Healthcare Systems, Inc. investigated a pilot Value-Based Benefit Design (VBBD) program to improve adherence to diabetes medications. The study found that a VBBD program that reduced copayments for diabetes medications by 36 percent reduced the number of non-adherent patients by 30 percent. The findings are significant because one of the most pressing challenges payors face today is patient medication non-adherence and the management of chronic illnesses.

"These results are significant in helping our clients deliver appropriate and cost-effective care to the individuals they serve," said Louis Brunetti, MD, JD, chief medical officer and senior vice president at MedImpact. "By aligning with our clients to consult on benefit designs they are developing that promote adherence, we will continue to measure and establish evidence of outcomes that seek to increase medication adherence, improve care, and lower health care costs for everyone."

The complete study, "The Impact of Value-Based Benefit Design on Adherence to Diabetes Medications: A Propensity Score Weighted Difference in Difference Evaluation," will be published in a future issue of Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research. The study was co-authored by Feng Zeng and Bimal Patel of MedImpact; Jae Jin An and Michael Nichol of the University of Southern California; and Robert Scully and Christina Barrington of Health Alliance Medical Plans. Health Alliance is a provider-sponsored health insurer that administers health plans for more than 310,000 members in Illinois and Iowa.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research and help health care leaders to make decisions that are solidly evidence-based. The journal is published bi-monthly and has a regular readership of over 4,000 clinicians, decision-makers, and researchers worldwide.

ISPOR is a nonprofit, international organization that strives to translate pharmacoeconomics and outcomes research into practice to ensure that society allocates scarce health care resources wisely, fairly, and efficiently.

About MedImpact Healthcare Systems, Inc. (

Rated the Overall Best PBM by Managed Care Organizations, MedImpact is dedicated to delivering innovative products and services designed to lower overall client cost while increasing member satisfaction and quality of care. As the nation's largest pharmacy benefit management company (PBM) that does not sell drugs, MedImpact focuses on helping clients manage the pharmacy benefit rather than increasing revenue from drug sales. Now in its 20th year, San Diego-based MedImpact serves more than 32 million individuals nationwide. Clients include corporations and employers, unions, managed care organizations, insurance carriers, third-party administrators, as well as local, state and federal employee programs.
COPYRIGHT 2010 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:MedImpact Study Demonstrates VBBD Improves Adherence to Diabetes Medication.
Publication:Business Wire
Geographic Code:1U9CA
Date:May 4, 2010
Previous Article:Concord Law School Launches Online Small Business Practice LLM.
Next Article:SuperMedia Executives Lead the Way With Industry Awards.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters